Advanced in Chromosome 13q Deletion

Adela N. Canete

Valencia, VC, ES 
Advanced in Chromosome 13q Deletion
Valencia, VC, ES 
OverviewLocationsClinical Research

Overview

Adela Canete practices in Valencia, Spain. Ms. Canete is rated as an Advanced expert by MediFind in the treatment of Chromosome 13q Deletion. Her top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Chromosome 13q Deletion.

Her clinical research consists of co-authoring 108 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Chromosome 13q Deletion.

Gender
Female

Locations

Valencia, VC, Spain
Other Locations
Spain
Campanar, VC 46009, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

European Low and Intermediate Risk Neuroblastoma Protocol
European Low and Intermediate Risk Neuroblastoma Protocol
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Drug
Study Drug: Chemotherapy
Study Phase: Phase 3
Prospective Observational Study of the Expression of ABCB1 / P-glycoprotein as a Factor for the Biological Stratification of Non-metastatic Osteosarcoma of the Extremities
Prospective Observational Study of the Expression of ABCB1 / P-glycoprotein as a Factor for the Biological Stratification of Non-metastatic Osteosarcoma of the Extremities
Enrollment Status: Completed
Publish Date: August 04, 2021
A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma
A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma
Enrollment Status: Unknown
Publish Date: July 14, 2020
Intervention Type: Drug
Study Drugs: ch14.18/CHO, Aldesleukin, Isotretinoin
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

108 Total Publications

Management of late toxicities and specific follow-up needs of adolescent and young adult cancer survivors: recommendations from scientific societies in Spain.
Management of late toxicities and specific follow-up needs of adolescent and young adult cancer survivors: recommendations from scientific societies in Spain.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: August 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Canete's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile